retina synthesis

We discuss the use of an IL-6 inhibitor in the treatment of uveitis macular edema with Dr. Sumit Sharma of the Cole Eye Institute, Cleveland Clinic.

We review the latest diagnostic and therapeutic approaches for retinoblastoma with Dr. Jesse Berry, Associate Professor of Ophthalmology, Children's Hospital Los Angeles.

We discuss the use of optogenetics for the treatment of inherited retinal degenerations with Dr. Jose Sahel, Chairman and Distinguished Professor of Ophthalmology at the University of Pittsburgh School of Medicine.

We discuss the use of the PDS in the treatment of diabetic retinopathy and diabetic macular edema with Professor Carl Regillo of the Wills Eye Hospital.

Dr. Eugene de Juan, winner of this year's ASRS Pyron Award, joins us to discuss his career highlights. Dr. de Juan is CEO of Forsight Labs and Professor of Ophthalmology, University of California, San Francisco.

We discuss the use of a novel drug (tyrosine kinase inhibitor) and novel delivery system (hydrogel) for the treatment of neovascular AMD with Dr. Peter Kaiser of the Cleveland Clinic.

We discuss the use of home OCT and artificial intelligence in the management of anti-VEGF therapy of neovascular AMD with Dr. Anat Loewenstein, Director, Department of Ophthalmology, Tel Aviv Medical Center, Israel.

We discuss the use of the port delivery system for the treatment of diabetic macular edema with Dr. Arshad Khanani, Director of Clinical Research, Sierra Eye Associates, Associate Clinical Professor, University of Nevada School of Medicine, Reno.

We discuss the suprachoroidal delivery of a tyrosinase kinase inhibitor and a gene therapy agent for the treatment of neovascular AMD with Dr. Mark Barakat, Assistant Clinical Professor of Ophthalmology, University of Arizona School of Medicine-Phoenix.

We discuss the use of microperimetry to assess treatment effects of anti-complement therapy (Apellis) of geographic atrophy with Dr. Nadia Waheed, Associate Professor of Ophthalmology, New England Eye Center, Tufts University School of Medicine.

Dr. Michael Elman of Elman Retina Group, Baltimore, Maryland, presents 10 year data demonstrating that Preferential Hyperacuity Perimetry (the Foresee Device) is a valuable tool in early detection of neovascular AMD.

We discuss the role that clinicians can play in fostering innovation in the retinal pharmacotherapy space with Dr. Eliot Lazar.

We discuss new developments in gene therapy for inherited retinal diseases with Sue Washer, President and CEO of AGTC.

We discuss the 18 month results of the Derby and Oaks trials of pegcetacoplan for treatment of geographic atrophy with Roger Goldberg, MD of Walnut Creek, California.

We discuss the two year results of a Phase I/II trial of a stem cell  implant for the treatment of geographic atrophy with Dr. Amir Kashani, Associate Professor, Wilmer Eye Institute.

We discuss the use of a home based OCT system with artificial intelligence to monitor the treatment of neovascular AMD with Dr. Nancy Holekamp, Professor of Clinical Ophthalmology, Washington University School of Medicine.

We discussed and learned with Samarendra Mohanty, PhD: President and Founder of Nanoscope Technologies, about the fascinating science of vision restoration through making bipolar cells light-sensitive and the development program of the intravitreally administered gene therapy vMCO-010c, currently being investigated in a Ph2b trial of patients with retinitis pigmentosa.

We examine the role of residual IRF and SRF in visual acuity results in treating nAMD. Dr. David Eichenbaum of Retina Vitreous Associates of Florida, Collaborative Associate Professor University of South Florida reviews the results of the Hawk and Harrier trials.

We review surgical techniques for sub retinal gene therapy with Dr. Lejla Vajzovic.

We discuss clinical trials using CNTF to treat MacTel Type 2 with Dr. John Pollack, Chief Medical Officer of Neurotech Pharmaceuticals.